Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio EssenceBIOE 31 Pretax Margin % is 42.91% as of Mar. 2026. GuruFocus rates BIOE with a GF Score™ of 31/100. The stock has 4 warning signs investors should review. Among 961 Drug Manufacturers companies, Bio Essence ranks better than 98.13% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Bio Essence's Pre-Tax Income for the
three
months ended in Mar. 2026 was $0.22 Mil. Bio Essence's Revenue for the
three
months ended in Mar. 2026 was $0.50 Mil. Therefore, Bio Essence's pretax margin for the quarter that ended in Mar. 2026 was 42.91%.
The historical rank and industry rank for Bio Essence's Pretax Margin % or its related term are showing as below:
BIOE'
s Pretax Margin % Range Over the Past 10 Years
Min: -483.02 Med: -78.47 Max: 55.47
Current: 55.47
BIOE's Pretax Margin % is ranked better than 98.13% of 961
companies
in the Drug Manufacturers industry
Industry Median: 7.28
vs BIOE: 55.47
Bio Essence (OTCPK:BIOE) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Bio Essence Pretax Margin % Related Terms
Bio Essence Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Bio Essence's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BIOE vs BFRI, APUS, CABR: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Bio Essence's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio Essence Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bio Essence's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Bio Essence's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio Essence (BIOE) has a Pretax Margin % of 42.91% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Bio Essence and its competitors. According to the industry distribution chart, Bio Essence ranks #18 out of 961 companies in the Drug Manufacturers industry, placing it in the top 1.9%.
Is Bio Essence's Pretax Margin % too high?
Bio Essence's current Pretax Margin % is 42.91%. The Drug Manufacturers industry median Pretax Margin % is 7.28. Bio Essence's value of 42.91% is 489.4% above this industry median. Based on the distribution chart, Bio Essence ranks #18 out of 961 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Bio Essence has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Bio Essence's Pretax Margin % compare to BFRI and APUS?
According to the Drug Manufacturers industry distribution chart, Bio Essence ranks #18 out of 961 companies for Pretax Margin %. This places Bio Essence in the top 2% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 7.28. Bio Essence's value of 42.91% is 489.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.28, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio Essence's current Pretax Margin % of 42.91% is 489.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Bio Essence and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio Essence's current Pretax Margin % is 42.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio Essence stock overvalued right now?
Bio Essence (BIOE) has a current Pretax Margin % of 42.91%. The current Pretax Margin % is 42.91% and 489.4% above the Drug Manufacturers industry median of 7.28. Bio Essence's overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Bio Essence (BIOE), the current Pretax Margin % is 42.91% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bio Essence Corp is an herbal health, diet, and nutrition company. The Company's mission is to provide herbal health, diet, and vitamin nutritional supplements. The primary focus of BEP was producing products for BEH and McBE, along with providing original equipment manufacturing and private label services to other companies. BEH targeted and developed traditional Chinese medicines (TCM) in the form of single herbs, granules, pills, and tablets. It also offered specially formulated dietary supplements and medical food. The Company operates in one business and industry segment: the manufacture / OEM and sale of health supplement products. The group's products are RED Yeast Rice Plus, Regenva, MediDrink, and Nufargo.
31GF Score
Get the complete analysis for BIOE
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIOE has been successfully added to your 
